Edward P. Gerstenfeld

Edward P. Gerstenfeld

Auto-generated profile, based on publicly available information

Edward P. Gerstenfeld

Division of Cardiology, Section of Cardiac Electrophysiology, University of California-San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Circulation
Verified
Journal Article
Open access
VRVivek Y. Reddy
Vivek Y. Reddy
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
BSBoris Schmidt
Boris Schmidt
JAJason G Andrade
Jason G Andrade
DNDevi Nair
Devi Nair
MMMoussa Mansour
Moussa Mansour
BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA 2 DS 2 -VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m 2 ; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and <1 hour duration, respectively. CONCLUSIONS: In Phase 2 of ADVANTAGE AF, the first multicenter PerAF study of PFA with continuous rhythm monitoring: (1) cavotricuspid isthmus ablation with nitroglycerin prophylaxis was safe and effective, (2) PVI plus posterior wall ablation was safe and effective, and (3) an AA burden <0.1% and AA episode <1 hour duration were end points associated with the lowest health care use. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05443594.

1 December 2018 in JACC
Verified
Journal Article
Closed access
TWTomos E. Walters
Tomos E. Walters
DRDolkun Rahmutula
Dolkun Rahmutula
JSJudit Szilagyi
Judit Szilagyi
CAChristina Alhede
Christina Alhede
RSRichard Sievers
Richard Sievers
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld

28 April 2022 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
SISung Il Im
Sung Il Im
SHSatoshi Higuchi
Satoshi Higuchi
ALAdam Lee
Adam Lee
CSCarol Stillson
Carol Stillson
EBEric Buck
Eric Buck
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld

26 October 2022 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
SHSatoshi Higuchi
Satoshi Higuchi
SISung Il Im
Sung Il Im
CSCarol Stillson
Carol Stillson
EBEric D. Buck
Eric D. Buck
SJSamantha Jerrell
Samantha Jerrell
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld

22 February 2023 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
ALAdam C. Lee
Adam C. Lee
AVAlex Voskoboinik
Alex Voskoboinik
CCChristopher C. Cheung
Christopher C. Cheung
SYSarah Yogi
Sarah Yogi
ZTZian H. Tseng
Zian H. Tseng
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld

1 July 2020 in Heart Rhythm
Verified
Journal Article
Closed access
AVAleksandr Voskoboinik
Aleksandr Voskoboinik
AHAlexios Hadjis
Alexios Hadjis
CAChristina Alhede
Christina Alhede
SISung Il Im
Sung Il Im
HPHansu Park
Hansu Park
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld